ISSN 1866-8836
Клеточная терапия и трансплантация

PO-01. Results of HSC transplantation in children with solid malignant neoplasms: Experience at the N. N. Blokhin National Medical Research Center of Oncology

Teymur Z. Aliev, Elena B. Machneva, Karina A. Sergeenko, Irina O. Kostareva, Nara G. Stepanyan, Yuri V. Lozovan, Tatiana I. Potemkina, Natalia A. Burlaka, Amina M. Suleimanova, Marina V. Rubanskaya, Garik B. Sagoyan, Olga M. Romantsova, Lana M. Kudaeva, Anatoly P. Kazantsev, Vladimir G. Polyakov, Kirill I. Kirgizov, Svetlana R. Varfolomeeva

L. Durnov Research Institute of Pediatric Oncology and Hematology at the N. N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia


Contact: Dr. Teymur Z. Aliev, phone: +7 (916) 368-90-27, e-mail: timaliev118@gmail.com

doi 10.18620/ctt-1866-8836-2023-12-3-1-176

Summary

Hematopoietic stem cell transplantation (HSCT) is a method of therapy for a number of severe malignant and non-tumor diseases. Autologous hematopoietic stem cell transplantation (auto-HSCT) improves outcomes in patients with oncological solid malignancies (MNs). The purpose of the present work was to arrange a program for HSCT in children with solid malignant neoplasms in children.

Materials and methods

At the Department of Pediatric Bone Marrow and HSCT, N. N. Blokhin National Medical Research Centre of Oncology over the period of 2021 to 2022 (24 months), 126 auto-HSCTs were performed for patients with solid malignant neoplasms using the following treatment regimens: in neuroblastoma (NB), COG/NB protocols, i.e., Treosulfan/Melphalan; in germ cell tumors (GKO), MAKEI 2005 protocol: tandem regimen containing Thiotepa; for Wilms tumor (OV), SIOP RTSG including Melphalan; in Ewing’s sarcoma (SJ), RESTART protocol, in EE, Treosulfan/Melphalan; for medulloblastoma (MB), HIT protocols, ATPO group: tandem regimen containing Thiotepa; in retinoblastoma (RB), RB center in the Russian Federation: Carboplatin/Vepezid/Cyclophosphomide; in pleuropulmonary blastema (PPB), according to the PPB-registry: Treosulfan / Melphalan; in Sialoblastoma (SB), Thiotepa-containing tandem regimen. All conditioning regimens were carried out with standard accompanying therapy.

Results

The N. N. Blokhin National Medical Research Center of Oncology conducted 126 auto-HSCTs over 24 months. Male (M) and female (F): M=72, F=54; 1:1.1. Median age: 9 years 5 months (7 months to 17.5 years). Patients with solid cancer: NB, 72 patients (death in 12 cases; recurrence, in 9 patients; progression, in 4 cases); SU, 26 patients (death in 5 cases; relapse in 8 patients; progression in 6 cases); OS, 9 patients (death in 2 cases; relapse in 3 patients; progression in 1 case); GKO was treated in 9 patients (absence of lethal cases; relapse not observed; progression in 1 case; RB, 5 patients (death of 1 patient; relapse, absent; progression was in 1 case); PPB was in 1 patient (no death, no relapse, no progression); MB was treated in 3 patients (death in 1case; no relapse or progression); SB was in 1 patient (without lethal cases, relapses, progression). Median term of hematopoiesis recovery was 12 days (9 to 15). Median follow-up lasted for 13 months (2 to 24). Complications in patients at the stage of auto-HSCT were as follows: mucositis, febrile neutropenia, toxic-allergic dermatitis and other conditions (perianal dermatitis, secondary arterial hypertension, pneumonia (unilateral/bilateral), CAIC, polyneuropathy, cystitis).

Conclusion

HSCT in children with solid cancer is a treatment option with acceptable outcomes. Each patient with a solid MN requires an individualized approach to HSCT management and follow-up.

Keywords

Hematopoietic stem cell transplantation, autologous, oncology, pediatric, solid cancers.


Supplement 12-3
09/30/2023

Download PDF version

doi 10.18620/ctt-1866-8836-2023-12-3-1-176

Back to the list